Vertex initiates phase 2 clinical trial program for vx-548 for the treatment of acute pain

Boston--(business wire)--vertex pharmaceuticals incorporated (nasdaq: vrtx) today announced that it has begun a phase 2 proof-of-concept (poc) study in acute pain following bunionectomy surgery with the selective nav1.8 inhibitor vx-548 and that it expects to commence a second phase 2 study in acute pain following abdominoplasty surgery in the coming weeks. “based on the favorable phase 1 data, we are advancing this program into phase 2 with initiation of a dose-ranging poc study in patients wi
VRTX Ratings Summary
VRTX Quant Ranking